More recently, clinical trial studies have shown that the addition of either ezetimibe or anti-proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) to statin therapy provides a further reduction in ASCVD risk [7,8,9]. The gene discussed is PCSK9; the disease is atherosclerosis.